title: Diversity of structure and function of alpha1alpha6beta3delta GABAA receptors: comparison with alpha1beta3delta and alpha6beta3delta receptors.
abstract: delta subunit-containing gamma-aminobutyric acid, type A (GABA(A))receptors are expressed extrasynaptically and mediate tonic inhibition. In cerebellar granule cells, they often form receptors together with alpha(1) and/or alpha(6) subunits. We were interested in determining the architecture of receptors containing both subunits. We predefined the subunit arrangement of several different GABA(A) receptor pentamers by concatenation. These receptors composed of alpha(1), alpha(6), beta(3), and delta subunits were expressed in Xenopus oocytes. Currents elicited in response to GABA were determined in the presence and absence of 3alpha,21-dihydroxy-5alpha-pregnan-20-one (THDOC) or ethanol, or currents were elicited by 4,5,6,7-tetrahydroisoxazolo[5,4-c]-pyridin-3-ol (THIP). Several subunit configurations formed active channels. We therefore conclude that delta can assume multiple positions in a receptor pentamer made up of alpha(1), alpha(6), beta(3), and delta subunits. The different receptors differ in their functional properties. Functional expression of one receptor type was only evident in the combined presence of the neurosteroid THDOC with the channel agonist GABA. Most, but not all, receptors active with GABA/THDOC responded to THIP. None of the receptors was modulated by ethanol concentrations up to 30 mm. Several observations point to a preferred position of delta subunits between two alpha subunits in alpha(1)alpha(6)beta(3)delta receptors. This property is shared by alpha(1)beta(3)delta and alpha(6)beta(3)delta receptors, but there are differences in the additionally expressed isoforms.
authors.affiliation: Institute of Biochemistry and Molecular Medicine, University of Bern, CH-3012 Bern, Switzerland.
authors.forename: Roland
authors.initials: R
authors.lastname: Baur
authors.forename: Kuldeep H
authors.initials: KH
authors.lastname: Kaur
authors.forename: Erwin
authors.initials: E
authors.lastname: Sigel
mesh_terms: D000818:Animals; D001665:Binding Sites; D004305:Dose-Response Relationship, Drug; D009474:Neurons / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism; D009865:Oocytes / Q000378:metabolism; D018408:Patch-Clamp Techniques; D020033:Protein Isoforms; D011963:Receptors, GABA-A / Q000737:chemistry*; D014981:Xenopus / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
chemical_list: D018377:Neurotransmitter Agents; D020033:Protein Isoforms; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid
references.citation: Eur J Pharmacol. 1995 Aug 15;290(3):175-81
references.pmid: 7589211
references.citation: J Biol Chem. 2002 Nov 29;277(48):46020-5
references.pmid: 12324466
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15218-23
references.pmid: 14625373
references.citation: Trends Pharmacol Sci. 2004 Sep;25(9):499-503
references.pmid: 15559253
references.citation: J Neurosci. 2002 May 15;22(10):RC223
references.pmid: 12006605
references.citation: Mol Pharmacol. 1996 Mar;49(3):567-79
references.pmid: 8643098
references.citation: Br J Pharmacol. 2008 Mar;153(5):1062-71
references.pmid: 18204487
references.citation: J Pharmacol Exp Ther. 2006 Mar;316(3):1360-8
references.pmid: 16272217
references.citation: Ann N Y Acad Sci. 1999 Apr 30;868:645-53
references.pmid: 10414349
references.citation: J Neurosci. 1994 Nov;14(11 Pt 2):7077-86
references.pmid: 7525894
references.citation: J Biol Chem. 2009 Mar 20;284(12):7889-96
references.pmid: 19141615
references.citation: Pharmacol Rev. 1998 Jun;50(2):291-313
references.pmid: 9647870
references.citation: Mol Cell Neurosci. 2008 Mar;37(3):610-21
references.pmid: 18206389
references.citation: Synapse. 1995 Nov;21(3):189-274
references.pmid: 8578436
references.citation: J Neurochem. 2003 Dec;87(6):1444-55
references.pmid: 14713300
references.citation: Biochem Soc Trans. 2009 Dec;37(Pt 6):1338-42
references.pmid: 19909272
references.citation: J Neurosci. 1998 Mar 1;18(5):1693-703
references.pmid: 9464994
references.citation: J Neurochem. 2009 Dec;111(5):1172-81
references.pmid: 19765192
references.citation: J Neurosci. 1996 Jan;16(1):103-14
references.pmid: 8613776
references.citation: Eur J Pharmacol. 1998 Apr 24;347(2-3):347-53
references.pmid: 9653902
references.citation: J Neurochem. 2000 Jun;74(6):2590-6
references.pmid: 10820222
references.citation: J Neurosci. 1997 Feb 15;17(4):1350-62
references.pmid: 9006978
references.citation: Curr Top Med Chem. 2002 Aug;2(8):795-816
references.pmid: 12171572
references.citation: Proc Natl Acad Sci U S A. 2004 May 18;101(20):7769-74
references.pmid: 15136735
references.citation: Annu Rev Neurosci. 1994;17:569-602
references.pmid: 7516126
references.citation: J Neurochem. 1996 Feb;66(2):685-91
references.pmid: 8592140
references.citation: J Biol Chem. 2001 Sep 28;276(39):36275-80
references.pmid: 11466317
references.citation: Trends Neurosci. 2004 Sep;27(9):569-75
references.pmid: 15331240
references.citation: FEBS Lett. 2006 Mar 6;580(6):1616-20
references.pmid: 16494876
references.citation: Neuron. 2008 Jul 31;59(2):207-13
references.pmid: 18667149
references.citation: J Pharmacol Exp Ther. 2006 Mar;316(3):1351-9
references.pmid: 16272218
references.citation: Neuron. 1990 Nov;5(5):703-11
references.pmid: 1699569
references.citation: J Neurosci. 2003 Dec 3;23(35):11158-66
references.pmid: 14657175
references.citation: Nat Neurosci. 2007 Jan;10(1):40-8
references.pmid: 17159992
references.citation: Nat Neurosci. 2005 Jun;8(6):797-804
references.pmid: 15895085
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14439-44
references.pmid: 14623958
references.citation: J Neurosci. 1998 Apr 1;18(7):2449-57
references.pmid: 9502805
references.citation: Nat Rev Neurosci. 2005 Mar;6(3):215-29
references.pmid: 15738957
references.citation: Mol Pharmacol. 1999 Jul;56(1):110-5
references.pmid: 10385690
references.citation: J Physiol. 1987 May;386:73-90
references.pmid: 2445971